C2I Alumni, SQZ Biotechnologies, announces $65M investment to push cancer vaccine and cell-squeezing
C2I alumni, SQZ Biotechnologies, announced a $65M investment by Roche to push a cancer vaccine for HPV-positive tumors through phase 1 and expand their signature cell-squeezing technology beyond oncology into infectious diseases.
SQZ Biotechnologies signature cancer pipeline is based on a cell therapy platform that squeezes cells and disrupts their membranes to get materials into them. In theory, the treatment would mean engineering the patients' immune cells to present tumor antigens to T cells which would then hunt down cells that express the target antigen.
To see the press release: https://lnkd.in/eGEQgqZ